Search results | obesity

Reports

Obesity Partnering

Obesity Partnering report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Allergan looks to sell lap-band and obesity unit

Allergan, one of the top 50 big pharma companies, is committed to selling the company’s obesity-treatment unit in the first half of 2013 after completing a review of the business.

Allergan seeks pharma partners for obesity business

Allergan,big pharma company, and the maker of the Botox wrinkle treatment, seeks pharma partners for its weight- loss unit. They wish to sell the business by the end of the first quarter, Chief Executive Officer David Pyott said.

Boehringer and Zealand team up to develop diabetes and obesity therapeutics

The companies have jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

Billion dollar partnership to treat obesity

Takeda and Orexigen have announced a $billion partnership to develop and commercialize Contrave for the treatment of obesity.

Allergan

Allergan is a top pharmaceutical company based in Irvine, California,USA

Co-promotion

Two or more companies sell the same drug under the same trademark

Healthcare M&A trends of 2013 so far

The healthcare sector in 2013 continues to adjust to a new environment of sluggish economic growth, budget constraints, reimbursement challenges, higher regulatory hurdles, and the uncertainties surrounding healthcare reform. Just recently, the European Parliament recently approved, by an overwhelming margin, a tightening up of CE-mark pre-market authorizations and post-mark surveillance of medical devices

Partnering activity of the FierceBiotech 2013 Fierce 15

The recent publication of FierceBioech’s 2013 Fierce 15 prompted Current Partnering to review the partnering activity of each company

Partnering with Allergan: Looking for partnerships and a higher bidder

Allergan is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products worldwide.

Partnering with Novo Nordisk: R&D partnering vision

Novo Nordisk is a top pharma and healthcare company active in partnering, licensing in pharmaceuticals and services specialising in diabetes care equipment and medications

Events

Sorry, your search returned no results.


Deals

Licensing agreement for antibody and vaccine for obesity

Sorrento Therapeutics has entered into an antibody and vaccine development collaboration with The Scripps Research Institute.

Allergan, the big pharma, sells its obesity intervention division for $110 million

Apollo Endosurgery has entered into a definitive agreement to purchase the obesity intervention division of the big pharma, Allergan for up to $110 million.

Licensing agreement for early-onset morbid obesity pre-clinical program

IRICoR and Université de Montréal License a Novel Program for Early-Onset Morbid Obesity to Pfizer

Allergan seeks pharma partners for obesity business

Allergan,big pharma company, and the maker of the Botox wrinkle treatment, seeks pharma partners for its weight- loss unit. They wish to sell the business by the end of the first quarter, Chief Executive Officer David Pyott said.

Boehringer, Zealand team on €376M diabetes and obesity pact

Zealand Pharma and Boehringer Ingelheim have announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

Takeda maps out obesity strategy as it confronts blockbuster loss

Faced with the looming loss of patent protection on Actos, the world’s top-selling diabetes drug, Japan’s Takeda has mapped out a drug development strategy that relies heavily on a new generation of therapies for “lifestyle diseases.”

Envoy Therapeutics enters diabetes and obesity collaboration with Merck & Co

Envoy will use its proprietary bacTRAP® technology to identify proteins expressed specifically in certain cell types. Merck will then work to identify and develop compounds that modulate protein targets with therapeutic potential for the treatment of metabolic disorders.

Biovitrum sells obesity program to AstraZeneca

Biovitrum will receive from AstraZeneca an upfront payment of Euro 6M and milestone payments contingent on development progress and sales, as well as single digit percentage royalties. If a product is approved, the agreement allows up to a total of Euro 186M in upfront and milestone payments to Biovitrum. The leptin modulator program is currently more »

Galapagos partners with Merck & Co to develop potential new therapies in obesity and diabetes

Under the terms of the agreement, Galapagos will receive an upfront fee of EUR 1.5 million from Merck.

GSK and Cold Spring Harbor in PTP1B inhibitor pact

Cold Spring Harbor Laboratory announced a collaboration with GSK to develop a treatment for obesity and type 2 diabetes